OpenURL Connection Search

Select item for more details and to access through your institution.

Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5
Published in:
Clinical Pharmacology & Therapeutics, 2005, v. 78, n. 6, p. 605, doi. 10.1016/j.clpt.2005.08.014
By:
- Mouly, Stéphane J.;
- Matheny, Chris;
- Paine, Mary F.;
- Smith, Glenn;
- Lamba, Jatinder;
- Lamba, Vishal;
- Pusek, Susan N.;
- Schuetz, Erin G.;
- Stewart, Paul W.;
- Watkins, Paul B.
Publication type:
Article
ImmunoPET imaging to assess target engagement: Experience from 89Zr‐anti‐HER3 mAb (GSK2849330) in patients with solid tumors.
Published in:
Journal of Nuclear Medicine, 2019, v. 60, n. 12, p. 1, doi. 10.2967/jnumed.118.214726
By:
- Willemien Menke‐van der Houven van Oordt, C.;
- McGeoch, Adam;
- Bergstrom, Mats;
- McSherry, Iain;
- Smith, Deborah A.;
- Cleveland, Matthew;
- Al‐Azzam, Wasfi;
- Liangfu Chen;
- Verheul, Henk;
- Hoekstra, Otto S.;
- Vugts, Danielle J.;
- Freedman, Immanuel;
- Huisman, Marc;
- Matheny, Chris;
- Guus van Dongen;
- Sean Zhang
Publication type:
Article
Immuno-PET Imaging to Assess Target Engagement: Experience from <sup>89</sup>Zr-Anti-HER3 mAb (GSK2849330) in Patients with Solid Tumors.
Published in:
Journal of Nuclear Medicine, 2019, v. 60, n. 7, p. 902, doi. 10.2967/jnumed.118.214726
By:
- Menke-van der Houven van Oordt, C. Willemien;
- McGeoch, Adam;
- Bergstrom, Mats;
- McSherry, Iain;
- Smith, Deborah A.;
- Cleveland, Matthew;
- Al-Azzam, Wasfi;
- Liangfu Chen;
- Verheul, Henk;
- Hoekstra, Otto S.;
- Vugts, Danielle J.;
- Freedman, Immanuel;
- Huisman, Marc;
- Matheny, Chris;
- van Dongen, Guus;
- Sean Zhang
Publication type:
Article

Found: 3

Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5

ImmunoPET imaging to assess target engagement: Experience from 89Zr‐anti‐HER3 mAb (GSK2849330) in patients with solid tumors.

Immuno-PET Imaging to Assess Target Engagement: Experience from <sup>89</sup>Zr-Anti-HER3 mAb (GSK2849330) in Patients with Solid Tumors.